endpts.com·May 6, 2026
Bayer is set to acquire ophthalmology biotech firm Perfuse Therapeutics for $300 million upfront, focusing on its mid-stage program aimed at addressing leading causes of blindness.
Bayer's decision to acquire Perfuse Therapeutics for $300 million highlights a significant move in the ophthalmology biotech space, focusing on treatments for leading causes of blindness. This acquisition underscores potential opportunities for investment and innovation in ophthalmology and suggests a growing interest from major pharma players in expanding their portfolios through targeted biotech acquisitions, particularly in areas with high unmet medical need.